Sublime
An inspiration engine for ideas
Research & Stats
Natalia F • 1 card
Landscape of OXR2 targeting drugs attacking narcolepsy
Yesterday, Takeda announced it's oral OXR2 agonist cleared two Phase 3 studies in narcolepsy, opening up a >$3B peak sales opportunity
I asked @sleuthinsights to pull together a competitive landscape and flag why analysts believe this... See more
Economics
Mark Fishman and • 95 cards
Market Research
sari and • 8 cards
$CRSP
1B peak revenue (the othe 1b goes to $VRTX) by 2023 and mc is 5B??
Plus in-vivo is coming after 2030?
Hmm, I better stay with $MDGL and alike.
5b projected revenue by 2030, mc of 4B.
Andre-ACGTx.comStocks / investing
productivity
Sakina A • 3 cards
I just came across this Nick Sleep gem.
Here is an interview Nick Sleep did back in 2013.
Nick Sleep and Qais Zakaria ran Nomad Investment Management which over 12 years compounded at 18%. https://t.co/M1TheZo3ZK